The present disclosure describes compositions and methods to promote wound healing. The compositions and methods include an interleukin-1 beta (IL-1β) receptor antagonist (IL-1Ra), such as anakinra. The IL-1Ra can be administered topically to a chronic wound including a diabetic ulcer.

The present disclosure provides methods and formulations for treating a patient suffering from one or more of chronic inflammatory injury, metaplasia, dysplasia or cancer of an epithelial tissue, which method comprises administering to the patient an agent that selectively kills or inhibits the proliferation or differentiation of pathogenic epithelial stem cells (PESCs) relative to normal epithelial stem cells in the tissue in which the PESCs are found. Representative epithelial tissues include pulmonary, genitourinary, gastrointestinal/esophageal, pancreatic and hepatic tissues.

Compositions, systems, devices, and methods for performing precise chemical treatment of tissues are disclosed. Systems, devices, and methods for administering a chemical agent to one or more a precise regions within a tissue mass are disclosed. Compositions, systems, devices, and methods for treating targeted regions within a tissue mass are disclosed. Systems, devices, and methods for identifying, localizing, monitoring neural traffic in the vicinity of, quantifying neural traffic in the vicinity of, and mapping neural traffic near targeted regions within a tissue mass are disclosed.

Disclosed herein are elastic, bioresorbable encasements for medical implants, methods for making the same and uses thereof.

A bone graft composition comprising a calcium phosphate putty is provided. A method of repairing a bone defect in a patient by applying the bone graft composition is also provided.

The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat, prevent from having, prevent from developing, control, reduce the severity, or reduce the progression of a disease, disorder or condition of a subject.

Methods for treating a wound or promote wound healing are provided, comprising the step of administering a composition including an effective amount of β-1 adrenergic receptor antagonist to a subject in need thereof. Also provided is apparatus for wound healing, comprising a dressing and a composition including an effective amount of β-1 adrenergic receptor antagonist.

A multifunctional hydrogel hybrid material and a method of its preparation and use in the treatment or prophylaxis of bone tissue loss is disclosed.

The present invention provides a preparation method for a drug-coated balloon controllable in drug metabolism. A drug receptor protein inhibitor is mixed with drugs, water and ethanol to obtain a medicinal liquid, the medicinal liquid is sprayed onto the surface of a balloon back and forth by means of an ultrasonic spraying device, and drying is performed so as to prepare the drug-coated balloon. The drug receptor protein inhibitor can also be replaced with other agents such as a drug metabolism isoenzyme inhibitor, a drug metabolism isoenzyme inducer, or a mixture of the drug receptor protein inhibitor and the drug metabolism isoenzyme inhibitor for preparing the medicinal liquid, and a drug metabolic cycle of the drug-coated balloon can be further adjusted and controlled by adjusting the ratio of the addition quantity of the drug receptor protein inhibitor or the other agents to the drugs. The drug-coated balloon prepared by the method has the functions that effective controllable drug metabolism can be implemented without destroying the structure of an intima, the drug metabolism can be implemented to achieve the effect of drug treatment at an early stage of using the drug-coated balloon, and the effect period of the drugs can be prolonged by adjusting the ratio.

The invention concerns lyophilized pharmaceutical formulations comprising plasmatic proteins or derivatives thereof, hyaluronic acid or a derivative thereof, and optionally one or more other pharmaceutically active ingredients, such as clonidine or a derivative thereof, wherein the lyophilized pharmaceutical formulations are characterized by a reconstitution time of less than 15 minutes. The invention further relates to methods for preparing these formulations, and their use for treating musculoskeletal diseases such as bone or joint diseases.